Education
About Us
Working with TipRanks
Follow Us
Delcath Systems (DCTH)
NASDAQ:DCTH
DCTH Stock Chart & Stats
$10.21
-$0.29(-2.36%)
At close: 4:00 PM EST
$10.21
-$0.29(-2.36%)
Day’s Range― - ―
52-Week Range$8.12 - $18.23
Previous CloseN/A
Volume96.76K
Average Volume (3M)474.81K
Market Cap
$366.56M
Enterprise Value$342.66M
Total Cash (Recent Filing)$88.91M
Total Debt (Recent Filing)$965.00K
Price to Earnings (P/E)1187.2
Beta1.75
Next Earnings
Mar 31, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.02
Shares Outstanding35,313,717
10 Day Avg. Volume466,968
30 Day Avg. Volume474,807
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)4.99
Price to Sales (P/S)9.23
P/FCF Ratio-17.84
Enterprise Value/Market Cap0.93
Enterprise Value/Revenue4.30
Enterprise Value/Gross Profit4.99
Enterprise Value/Ebitda24.01
Forecast
1Y Price Target
$24.20Price Target Upside137.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)0.35
Revenue Forecast (FY)$117.09M
Bulls Say, Bears Say
Bulls Say
Clinical EvidencePublication of CHOPIN results in a leading medical journal could prompt inclusion in clinical compendia and increase physician confidence in combining Hepzato with checkpoint inhibitors, supporting broader adoption.
Commercial AdoptionRising Hepzato procedure volumes and the onboarding of additional referral centers point to growing physician utilization and potential for higher patient throughput.
Pipeline ExpansionInitiation of trials for liver metastases from colorectal and breast cancer could expand Hepzato's addressable market and open new revenue streams.
Bears Say
Revenue HeadwindsParticipation in the Medicaid rebate program combined with seasonal scheduling delays has pressured revenues and could constrain near-term top-line growth.
Safety ProfileHigh rates of serious adverse events and elevated treatment discontinuation in combination regimens may deter clinicians from adopting Hepzato plus checkpoint inhibitors broadly.
Site ActivationA slowdown in activating new treatment centers may jeopardize projected site expansion targets and limit the commercial footprint needed to scale revenue.
Delcath Systems News
DCTH FAQ
What was Delcath Systems’s price range in the past 12 months?
Delcath Systems lowest stock price was $8.12 and its highest was $18.23 in the past 12 months.
What is Delcath Systems’s market cap?
Delcath Systems’s market cap is $366.56M.
When is Delcath Systems’s upcoming earnings report date?
Delcath Systems’s upcoming earnings report date is Mar 31, 2026 which is in 73 days.
How were Delcath Systems’s earnings last quarter?
Delcath Systems released its earnings results on Nov 04, 2025. The company reported $0.02 earnings per share for the quarter, beating the consensus estimate of -$0.004 by $0.024.
Is Delcath Systems overvalued?
According to Wall Street analysts Delcath Systems’s price is currently Undervalued.
Does Delcath Systems pay dividends?
Delcath Systems does not currently pay dividends.
What is Delcath Systems’s EPS estimate?
Delcath Systems’s EPS estimate is -0.07.
How many shares outstanding does Delcath Systems have?
Delcath Systems has 35,313,717 shares outstanding.
What happened to Delcath Systems’s price movement after its last earnings report?
Delcath Systems reported an EPS of $0.02 in its last earnings report, beating expectations of -$0.004. Following the earnings report the stock price went down -4.622%.
Which hedge fund is a major shareholder of Delcath Systems?
Currently, no hedge funds are holding shares in DCTH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Delcath Systems Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.20 (137.02% Upside)
$24.20 (137.02% Upside)
Blogger Sentiment
Bullish
DCTH Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 778.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $137.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 2.2%
Last 30 Days ▲ 1.4%
Last 30 Days ▲ 1.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-18.20%
12-Months-Change
Fundamentals
Return on Equity
1.94%
Trailing 12-Months
Asset Growth
292.33%
Trailing 12-Months
Company Description
Delcath Systems
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
DCTH Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture with significant advancements in clinical trials and revenue growth, but also highlighted challenges such as reduced revenue per kit and increased operating expenses impacting profitability.View all DCTH earnings summariesDCTH Stock 12 Month Forecast
Average Price Target
$24.20
▲(137.02% Upside)
Technical Analysis
Ownership Overview
30.89% Insiders
6.91% Mutual Funds
25.50% Other Institutional Investors
28.25% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---